🎉 M&A multiples are live!
Check it out!

Cabaletta Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cabaletta Bio and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Cabaletta Bio Overview

About Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies  CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.


Founded

2017

HQ

United States of America
Employees

164

Financials

LTM Revenue $1.7M

LTM EBITDA -$133M

EV

-$89.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cabaletta Bio Financials

Cabaletta Bio has a last 12-month revenue of $1.7M and a last 12-month EBITDA of -$133M.

In the most recent fiscal year, Cabaletta Bio achieved revenue of n/a and an EBITDA of -$113M.

Cabaletta Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cabaletta Bio valuation multiples based on analyst estimates

Cabaletta Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$73.2M -$113M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$53.0M -$67.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cabaletta Bio Stock Performance

As of April 15, 2025, Cabaletta Bio's stock price is $1.

Cabaletta Bio has current market cap of $59.1M, and EV of -$89.2M.

See Cabaletta Bio trading valuation data

Cabaletta Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$89.2M $59.1M XXX XXX XXX XXX $-2.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cabaletta Bio Valuation Multiples

As of April 15, 2025, Cabaletta Bio has market cap of $59.1M and EV of -$89.2M.

Cabaletta Bio's trades at -53.2x LTM EV/Revenue multiple, and 0.7x LTM EBITDA.

Analysts estimate Cabaletta Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cabaletta Bio and 10K+ public comps

Cabaletta Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$89.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cabaletta Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cabaletta Bio Valuation Multiples

Cabaletta Bio's NTM/LTM revenue growth is 216%

Cabaletta Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Cabaletta Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cabaletta Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cabaletta Bio and other 10K+ public comps

Cabaletta Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 55% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cabaletta Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cabaletta Bio M&A and Investment Activity

Cabaletta Bio acquired  XXX companies to date.

Last acquisition by Cabaletta Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cabaletta Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cabaletta Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cabaletta Bio

When was Cabaletta Bio founded? Cabaletta Bio was founded in 2017.
Where is Cabaletta Bio headquartered? Cabaletta Bio is headquartered in United States of America.
How many employees does Cabaletta Bio have? As of today, Cabaletta Bio has 164 employees.
Who is the CEO of Cabaletta Bio? Cabaletta Bio's CEO is Dr. Steven Nichtberger,M.D..
Is Cabaletta Bio publicy listed? Yes, Cabaletta Bio is a public company listed on NAS.
What is the stock symbol of Cabaletta Bio? Cabaletta Bio trades under CABA ticker.
When did Cabaletta Bio go public? Cabaletta Bio went public in 2019.
Who are competitors of Cabaletta Bio? Similar companies to Cabaletta Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cabaletta Bio? Cabaletta Bio's current market cap is $59.1M
What is the current revenue of Cabaletta Bio? Cabaletta Bio's last 12-month revenue is $1.7M.
What is the current EBITDA of Cabaletta Bio? Cabaletta Bio's last 12-month EBITDA is -$133M.
What is the current EV/Revenue multiple of Cabaletta Bio? Current revenue multiple of Cabaletta Bio is -53.2x.
What is the current EV/EBITDA multiple of Cabaletta Bio? Current EBITDA multiple of Cabaletta Bio is 0.7x.
Is Cabaletta Bio profitable? Yes, Cabaletta Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.